Fritextsökning
Artiklar per år
Innehållstyper
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
-
KI’s freezer fiasco investigated: A chain of failures
A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying more than 47,000 samples. This was the conclusion of an internal investigation.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”
It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or whether they are indeed right (or wrong) for the current project, Anna Törner writes in a column.
-
Anna Törner: ”Orphan designation läkemedelsutvecklingens ’petite robe noire’”
Det är så lätt att klamra sig fast vid olika regulatoriska incitament, som orphan designation, utan att egentligen veta vad de innebär och på vilket sätt de kan vara rätt (eller fel), skriver Anna Törner i en krönika.
-
Erfaren medtechledare tar över klubban i Realheart
Medtechbolaget Realheart, som utvecklar ett artificiellt hjärta, har utsett Magnus Öhman till arbetande styrelseordförande.
-
“Life science is important on a personal level”
From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of the Government’s Life Science Office.
-
Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”
What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Sweden's editor-in-chief Samuel Lagercrantz highlights three areas.
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story of a Swedish entrepreneur who was going to raise US venture capital to strengthen his company but lost his life’s work instead.
-
Acquisition of consulting company Key2Compliance
The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.
-
A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024
The new year brings new features for the readers of Life Science Sweden.